Cargando…

Medical cannabis use in the United States: a retrospective database study

INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a pau...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahabir, V. Kishan, Merchant, Jamil J., Smith, Christopher, Garibaldi, Alisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819290/
https://www.ncbi.nlm.nih.gov/pubmed/33526110
http://dx.doi.org/10.1186/s42238-020-00038-w
_version_ 1783638983706673152
author Mahabir, V. Kishan
Merchant, Jamil J.
Smith, Christopher
Garibaldi, Alisha
author_facet Mahabir, V. Kishan
Merchant, Jamil J.
Smith, Christopher
Garibaldi, Alisha
author_sort Mahabir, V. Kishan
collection PubMed
description INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs. METHODS: We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression. RESULTS: The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3). CONCLUSION: This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions.
format Online
Article
Text
id pubmed-7819290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78192902021-01-25 Medical cannabis use in the United States: a retrospective database study Mahabir, V. Kishan Merchant, Jamil J. Smith, Christopher Garibaldi, Alisha J Cannabis Res Review INTRODUCTION: Growing interest in the medicinal properties of cannabis has led to an increase in its use to treat medical conditions, and the establishment of state-specific medical cannabis programs. Despite medical cannabis being legal in 33 states and the District of Colombia, there remains a paucity of data characterizing the patients accessing medical cannabis programs. METHODS: We retrospectively reviewed a registry with data from 33 medical cannabis evaluation clinics in the United States, owned and operated by CB2 Insights. Data were collected primarily by face-to-face interviews for patients seeking medical cannabis certification between November 18, 2018 and March 18, 2020. Patients were removed from the analysis if they did not have a valid date of birth, were less than 18, or did not have a primary medical condition reported; a total of 61,379 patients were included in the analysis. Data were summarized using descriptive statistics expressed as a mean (standard deviation (SD)) or median (interquartile range (IQR)) as appropriate for continuous variables, and number (percent) for categorical variables. Statistical tests performed across groups included t-tests, chi-squared tests and regression. RESULTS: The average age of patients was 45.5, 54.8% were male and the majority were Caucasian (87.5%). Female patients were significantly older than males (47.0 compared to 44.6). Most patients reported cannabis experience prior to seeking medical certification (66.9%). The top three mutually exclusive primary medical conditions reported were unspecified chronic pain (38.8%), anxiety (13.5%) and post-traumatic stress disorder (PTSD) (8.4%). The average number of comorbid conditions reported was 2.7, of which anxiety was the most common (28.3%). Females reported significantly more comorbid conditions than males (3.1 compared to 2.3). CONCLUSION: This retrospective study highlighted the range and number of conditions for which patients in the US seek medical cannabis. Rigorous clinical trials investigating the use of medical cannabis to treat pain conditions, anxiety, insomnia, depression and PTSD would benefit a large number of patients, many of whom use medical cannabis to treat multiple conditions. BioMed Central 2020-09-29 /pmc/articles/PMC7819290/ /pubmed/33526110 http://dx.doi.org/10.1186/s42238-020-00038-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Mahabir, V. Kishan
Merchant, Jamil J.
Smith, Christopher
Garibaldi, Alisha
Medical cannabis use in the United States: a retrospective database study
title Medical cannabis use in the United States: a retrospective database study
title_full Medical cannabis use in the United States: a retrospective database study
title_fullStr Medical cannabis use in the United States: a retrospective database study
title_full_unstemmed Medical cannabis use in the United States: a retrospective database study
title_short Medical cannabis use in the United States: a retrospective database study
title_sort medical cannabis use in the united states: a retrospective database study
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819290/
https://www.ncbi.nlm.nih.gov/pubmed/33526110
http://dx.doi.org/10.1186/s42238-020-00038-w
work_keys_str_mv AT mahabirvkishan medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy
AT merchantjamilj medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy
AT smithchristopher medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy
AT garibaldialisha medicalcannabisuseintheunitedstatesaretrospectivedatabasestudy